Table 5.
Change from baseline | Repeated measures two-way ANOVA | ||||||||
---|---|---|---|---|---|---|---|---|---|
Week 4 | Week 8 | Week 12 | Group | Time | Interaction | ||||
Mean | SD | Mean | SD | Mean | SD | ||||
CRP, mg/dL | |||||||||
Placebo | 0.019 | 0.044 | 0.036 | 0.091 | 0.016 | 0.047 | 0.057 | 0.363 | 0.302 |
CLE | 0.021 | 0.089 | 0.002 | 0.032 | −0.007* | 0.035 | |||
C3, mg/dL | |||||||||
Placebo | 4.13 | 7.94 | 0.10 | 9.33 | 7.26 | 9.00 | 0.514 | < 0.001 | 0.138 |
CLE | 4.00 | 8.14 | 1.41 | 11.90 | 2.66* | 8.20 | |||
C4, mg/dL | |||||||||
Placebo | 0.06 | 2.78 | 0.71 | 3.57 | 1.48 | 3.47 | 0.366 | 0.094 | 0.135 |
CLE | 0.28 | 2.58 | −0.07 | 3.42 | 0.34 | 2.69 | |||
Fibrinogen, mg/dL | |||||||||
Placebo | 9.0 | 27.9 | 11.4 | 46.3 | 15.1 | 35.5 | 0.648 | 0.371 | 0.950 |
CLE | 5.3 | 50.6 | 3.7 | 29.7 | 12.0 | 37.8 |
CRP: C-reactive protein; C3: complement component 3; C4: complement component 4
aValues represent the means and standard deviations at 4, 8, and 12 weeks for n = 31, 31, and 31 (placebo group) or n = 29, 27, and 29 (CLE group), respectively. *p < 0.05: Significant difference from the placebo group by repeated measures two-way ANOVA, followed by the two-tailed unpaired Student’s t test when variance was homogeneous or the Aspin-Welch t test when variance was heterogeneous